Invention Grant
- Patent Title: Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
-
Application No.: US17902618Application Date: 2022-09-02
-
Publication No.: US12084452B2Publication Date: 2024-09-10
- Inventor: Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
- Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY,Université de Montréal
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY,Université de Montréal
- Current Assignee Address: US NJ Princeton; CA Montréal
- Agency: Hoffmann & Baron, LLP
- The original application number of the division: US14396771
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/433 ; A61K31/435 ; A61K31/4439 ; A61K31/454 ; A61K31/496 ; A61K31/497 ; A61K31/5025 ; A61K31/5377 ; A61K31/5386 ; A61K31/541 ; A61K31/55 ; A61K31/553 ; A61K45/06 ; A61K51/04 ; C07B59/00 ; C07D513/04 ; C07D519/00

Abstract:
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Public/Granted literature
Information query